Later this week, Cardinal Health Specialty Solutions will present a new series of health economic outcomes research (HEOR) studies that reinforce the importance of evaluating real-world treatment patterns when developing value-based reimbursement strategies.
Dr. Bruce Feinberg, vice president and chief medical officer of Cardinal Health Specialty Solutions, says that physicians, payers and pharmaceutical companies alike have known for more than a decade that clinical trials alone do not accurately reflect how cancer treatment happens in the real world. Feinberg maintains that payers are seeing this disparity, and are adjusting reimbursement strategies as a result.
"With an increased focus on value-based care, which relies on real-world clinical evidence, clinical trial data no longer provides enough information to develop appropriate reimbursement models," said Feinberg. "This new research reinforces that HEOR data can help payers better understand the effectiveness of treatments in real-world settings; and that it can be used to better determine value-based reimbursement strategies."
Research explores the health benefits of resistant starch in plant-based diets